Charles Schwab
INBX

Charles Schwab’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Charles Schwab’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-231,434
Closed -$8.09M – 3738
2024
Q1 		$8.09M Buy
231,434
+1,568
+0.7% +$57.2K ﹤0.01% 2090
2023
Q4 		$8.73M Buy
229,866
+17,762
+8% +$381K ﹤0.01% 2060
2023
Q3 		$3.89M Sell
212,104
-34,024
-14% -$712K ﹤0.01% 2364
2023
Q2 		$6.39M Buy
246,128
+4,427
+2% +$103K ﹤0.01% 2129
2023
Q1 		$4.56M Sell
241,701
-6,221
-3% -$145K ﹤0.01% 2247
2022
Q4 		$6.11M Buy
247,922
+26,356
+12% +$775K ﹤0.01% 2116
2022
Q3 		$3.98M Buy
221,566
+53,336
+32% +$961K ﹤0.01% 2342
2022
Q2 		$1.91M Buy
168,230
+3,700
+2% +$54.4K ﹤0.01% 2577
2022
Q1 		$3.67M Buy
164,530
+3,620
+2% +$92.4K ﹤0.01% 2421
2021
Q4 		$7.03M Buy
160,910
+2,825
+2% +$113K ﹤0.01% 2179
2021
Q3 		$5.27M Buy
158,085
+67,637
+75% +$2.06M ﹤0.01% 2349
2021
Q2 		$2.49M Buy
90,448
+38,950
+76% +$811K ﹤0.01% 2635
2021
Q1 		$1.03M Buy
51,498
+2,368
+5% +$69.1K ﹤0.01% 2843
2020
Q4 		$1.62M Buy
+49,130
New +$1.31M ﹤0.01% 2652

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Charles Schwab's INBX Position: Q2 2024 in Review

Charles Schwab sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 231,434 shares — an estimated $8.09M sold.

Charles Schwab first reported a position in INBX in Q4 2020 and held it in 14 quarters. The position peaked at $8.73M in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • Charles Schwab reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Charles Schwab sold 231,434 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $8.09M.
  • Charles Schwab first reported a position in Inhibrx, Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Charles Schwab's Inhibrx, Inc. Common Stock position peaked at $8.73M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.